Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zepvog
- Development stage
- Phase 4
- Lead developer
- Merlion Lifescience
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Zepvog** is an oral fixed-dose antidiabetic combination product developed and marketed by Merlion Lifescience for glycemic control in **type 2 diabetes mellitus**. It contains voglibose and metformin hydrochloride: voglibose reversibly inhibits intestinal alpha-glucosidases, delaying carbohydrate digestion and postprandial glucose absorption, while metformin suppresses hepatic glucose production and improves peripheral insulin sensitivity, in part through activation of AMP-activated protein kinase signaling. The marketed product is a sustained-release tablet containing metformin 500 mg and voglibose 0.3 mg.
- Brand names
- Zepvog
- Other names
- metformin + voglibose
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)Sucrase-Isomaltase
Beyond the preview
Go deeper on Zepvog.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zepvog.